Literature DB >> 8527703

Direct evidence of monocyte recruitment to inflammatory bowel disease mucosa.

M C Grimm1, W E Pullman, G M Bennett, P J Sullivan, P Pavli, W F Doe.   

Abstract

Alterations in phenotype and function of intestinal macrophages occur in inflammatory bowel disease (IBD) but it is unclear whether these changes result from the recruitment of circulating monocytes to the intestine or from proliferation of resident intestinal macrophages. We sought to demonstrate the arrival of blood monocytes, the precursors of macrophages, in IBD mucosa. Peripheral blood mononuclear cells were isolated from 23 patients with clinically active intestinal inflammation (13 Crohn's disease, eight ulcerative colitis, two infective colitis), then radiolabelled with 99mtechnetium (Tc)-stannous colloid (n = 13) or 111indium (In)-oxine (n = 10) before re-injection and abdominal scanning. Four patients had demonstrable intestinal monocyte uptake using [99mTc]-stannous colloid, while six [111In]-oxine-labelled monocyte scans were positive. Uptake sites correlated with actively inflamed regions. Patients demonstrating monocyte uptake had been treated with corticosteroids for a significantly (P < 0.02) shorter duration (median 3 vs 20 days) than those with negative scans. There was no significant difference between positive and negative scans for disease category, clinical or histological disease, activity, or radioisotope used. Biopsies of inflamed mucosa from two patients suffering ulcerative colitis who had positive scans showed a high proportion of CD14-positive macrophages, 4-9% of which contained autoradiographic grains. These results demonstrate that blood monocytes are recruited to the mucosa of actively inflamed bowel, and suggest that this process may be inhibited by corticosteroids. Moreover, the phenotype of the recently-arrived monocytes indicates their susceptibility to stimulation by lipopolysaccharide, and suggests a mechanism for the continuing inflammation in the bacterial product-rich milieu of IBD.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8527703     DOI: 10.1111/j.1440-1746.1995.tb01589.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  59 in total

1.  Professional and non-professional antigen-presenting cells in the porcine small intestine.

Authors:  K Haverson; S Singha; C R Stokes; M Bailey
Journal:  Immunology       Date:  2000-12       Impact factor: 7.397

Review 2.  Probiotics and immune response.

Authors:  Stephanie Blum; Dirk Haller; Andrea Pfeifer; Eduardo J Schiffrin
Journal:  Clin Rev Allergy Immunol       Date:  2002-06       Impact factor: 8.667

Review 3.  Slit proteins, potential endogenous modulators of inflammation.

Authors:  Necat Havlioglu; Liya Yuan; Hao Tang; Jane Y Wu
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

4.  Amyloid precursor protein expression modulates intestine immune phenotype.

Authors:  Kendra L Puig; Adam J Swigost; Xudong Zhou; Mary Ann Sens; Colin K Combs
Journal:  J Neuroimmune Pharmacol       Date:  2011-11-29       Impact factor: 4.147

5.  Novel anti-inflammatory agent 3-[(dodecylthiocarbonyl)-methyl]-glutarimide ameliorates murine models of inflammatory bowel disease.

Authors:  Nobuki Ichikawa; Kenichiro Yamashita; Tohru Funakoshi; Shin Ichihara; Moto Fukai; Masaomi Ogura; Nozomi Kobayashi; Masaaki Zaitsu; Tadashi Yoshida; Susumu Shibasaki; Yasuyuki Koshizuka; Yusuke Tsunetoshi; Masanori Sato; Takahiro Einama; Michitaka Ozaki; Kazuo Umezawa; Tomomi Suzuki; Satoru Todo
Journal:  Inflamm Res       Date:  2015-12-18       Impact factor: 4.575

6.  Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis.

Authors:  Bo Xiao; Zhigang Xu; Emilie Viennois; Yuchen Zhang; Zhan Zhang; Mingzhen Zhang; Moon Kwon Han; Yuejun Kang; Didier Merlin
Journal:  Mol Ther       Date:  2017-01-28       Impact factor: 11.454

7.  Artemisinin analogue SM934 ameliorates DSS-induced mouse ulcerative colitis via suppressing neutrophils and macrophages.

Authors:  Yu-Xi Yan; Mei-Juan Shao; Qing Qi; Yan-Sheng Xu; Xiao-Qian Yang; Feng-Hua Zhu; Shi-Jun He; Pei-Lan He; Chun-Lan Feng; Yan-Wei Wu; Heng Li; Wei Tang; Jian-Ping Zuo
Journal:  Acta Pharmacol Sin       Date:  2018-05-31       Impact factor: 6.150

8.  Elimination of local macrophages in intestine prevents chronic colitis in interleukin-10-deficient mice.

Authors:  Norihiko Watanabe; Koichi Ikuta; Kazuichi Okazaki; Hiroshi Nakase; Yasuhiko Tabata; Minoru Matsuura; Hiroyuki Tamaki; Chiharu Kawanami; Tasuku Honjo; Tsutomu Chiba
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

Review 9.  [Advances in macrophage function and its anti-inflammatory and proresolving activity and role in periodontitis development].

Authors:  Bai Lin; Xin Yuejiao; Duan Dingyu; Xu Yi
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2017-08-01

10.  Degraded carrageenan causing colitis in rats induces TNF secretion and ICAM-1 upregulation in monocytes through NF-kappaB activation.

Authors:  Claudine Benard; Antonietta Cultrone; Catherine Michel; Carlos Rosales; Jean-Pierre Segain; Marc Lahaye; Jean-Paul Galmiche; Christine Cherbut; Hervé M Blottière
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.